Memphasys believes it has found a quicker, cheaper way to get its Felix sperm separation system cleared by US regulators. It could open a door to an IVF market worth about US$5.9 billion.

Paradigm Biopharmaceuticals has suffered a setback after an independent monitoring board found that its Phase 3 knee ...

The final visit took place in the United States this week. The company told investors that topline results from the XanaMIA ...

Perth company Patrys has started in-human testing of its intravenous version of the antipsychotic quetiapine. The first ...

Prescient Therapeutics has raised $6 million from shareholders and investors. The money will fund its lead cancer drug ...

BCAL Diagnostics has started a phased rollout of Avantect Multi-Cancer in Sydney and Melbourne and plans to expand nationally ...

The Australian nuclear medicine company has agreed to lead a merger with ITM Isotope Technologies Munich SE, paying US$1.65 ...

Melbourne kidney disease drug developer Dimerix has drawn $17 million from a $34 million loan facility as its lead candidate ...

A Melbourne biotechnology company betting on immune cell cargo as a treatment for Alzheimer's disease has enlisted one of ...

Genetic Signatures and Microba Life Sciences have agreed on the principal commercial terms of a merger that would combine two ...

Anthropic has expanded its AI for Science commitment in Australia with an additional $10 million in Claude API credit grants, ...

Seven Australian startups will share $15.6 million to speed up the development of new treatments, diagnostic tools and technologies for dementia and cognitive decline.